Repligen Corporation (NASDAQ:RGEN) is identified as one of the best mid-cap growth stocks to buy now. UBS raised its price target on Repligen to $200 from $190 on January 16, citing sustained recovery potential in the bioprocessing sector. The company saw over 20% order growth and has a growing footprint in Edge manufacturing, positioning it as a key player in the biopharma industry.

Repligen Corporation (NASDAQ:RGEN) recently launched three new high-performance chromatography resins, including AVIPure HiPer AAV9, AVIPure HiPer AAV8, and HiPer QA. These resins are designed to meet the demands of next-gen bioprocessing, particularly for gene therapy viral vectors. They utilize Tantti DuloCore base bead technology for improved performance and efficiency in biotherapeutic workflows.

Repligen Corporation (NASDAQ:RGEN) is a prominent life sciences company that develops and commercializes bioprocessing technologies worldwide, catering to various regions including North America, Europe, and the Asia Pacific.

While Repligen (RGEN) shows promise as an investment, some AI stocks may offer greater upside potential with less downside risk. For those interested in undervalued AI stocks poised to benefit from current economic trends, a free report on the best short-term AI stock is available for further exploration.

Read more at Yahoo Finance: UBS Tags Repligen (RGEN) as Bioprocessing Leader for 2026, Cites 20% Order Growth and Reshoring Tailwinds